Monday, 20 May 2024
  
Login

Australia's most trusted
source of pharma news

Monday, 20 May 2024
Listen to this story 
News

PBS expansion for mAb now official

Posted 8 May 2024 AM

UCB Australia's monoclonal antibody (mAb) Bimzelx has been TGA approved for three new arthritis indications, allowing the company to officially pursue reimbursement.

Bimzelx's new indications include active psoriatic arthritis (PsA), and active axial spondyloarthritis (axSpA), including non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis, also known as radiographic axSpA.

To see the whole article, please login

Popular

GSK's 'warrior' aiming high
Who's in line for a June listing?
Aussie Pfizer exec lands CEO job
Budget holds no prizes for pharma
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (22)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (5)

Other (30)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home